Biological Dynamics and PRECEDE Collaborate to Improve Surveillance of Early Pancreatic Cancer

0
165
Cancer cells vis - 3d rendered image, enhanced scanning electron micrograph (SEM) of cancer cell. Visual of overall shape of the cell's surface at a very high magnification. Medical research concept.
Biological Dynamics and PRECEDE Collaborate to Improve Surveillance of Early Pancreatic Cancer
Img Cr. Getty Images

Biological Dynamics, a company developing liquid biopsy tests for early cancer detection, has announced a collaboration with the Pancreatic Cancer Early Detection Consortium (PRECEDE). The collaboration will focus on developing and validating a liquid biopsy test for the early detection of pancreatic cancer.

Pancreatic cancer is a deadly disease with a five-year survival rate of just 10%. Early detection is critical for improving outcomes, but there are currently no effective screening tests for pancreatic cancer.

Biological Dynamics’ liquid biopsy test is designed to detect tumor-associated DNA (ctDNA) in the blood. ctDNA is a small amount of DNA that is released from cancer cells into the bloodstream.

The PRECEDE consortium is a group of academic medical centers and research institutions that are working to develop new methods for early detection of pancreatic cancer. The consortium is funded by the National Cancer Institute (NCI).

The collaboration between Biological Dynamics and PRECEDE will involve the use of Biological Dynamics’ liquid biopsy test in a clinical trial of people at high risk for pancreatic cancer. The trial will be conducted at several PRECEDE member institutions.

The goal of the trial is to determine whether Biological Dynamics’ liquid biopsy test can detect pancreatic cancer at an earlier stage than is currently possible. If the test is successful, it could be used to screen people at high risk for pancreatic cancer and identify them for early intervention.

“We are excited to collaborate with PRECEDE on this important initiative,” said Dr. Michael Pienta, CEO of Biological Dynamics. “This collaboration will help us to accelerate the development and validation of our liquid biopsy test for pancreatic cancer.”

“We are committed to finding new ways to improve early detection of pancreatic cancer,” said Dr. Michael S. Hellinger, principal investigator of the PRECEDE consortium. “This collaboration with Biological Dynamics is a significant step forward in our efforts to develop a new screening test for this deadly disease.”

The collaboration between Biological Dynamics and PRECEDE is a promising development in the fight against pancreatic cancer. If successful, the test could help to save lives by detecting the disease at an earlier stage.

Leave a reply

Please enter your comment!
Please enter your name here